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1. INTRODUCTION 
Coronary artery diseases (CAD) are the leading cause of death in the world 
[World Health Organization (WHO) Mortality Database 2012]. They cause 
considerable costs in terms of medical expenditures, lost production, suffering 
and premature death (Wieser et al. 2012).  
CAD mortality has continuously been decreasing in most of the Western 
high-income countries over the last few decades (WHO European Detailed 
Mortality Database 2012), in some regions even more than 50% (Bjorck et al. 
2009). The decreasing mortality trends can partially be explained by changes in 
the major cardiovascular risk factors including total cholesterol, smoking, and 
blood pressure levels (Capewell et al. 1999; Tunstall-Pedoe et al. 2000; Unal et 
al. 2004; Ford et al. 2007; Bandosz et al. 2012). The other major factor 
contributing to the decline in the mortality is the rapid uptake of effective 
medical therapies and coronary revascularization methods. This has led to the 
lower case fatality of acute myocardial infarction (AMI), which has one of the 
highest risks among CAD. Community studies have shown that the overall case 
fatality rate of patients with AMI in the first month can be as high as 50%, and 
of these deaths about half occur within the first two hours (Tunstall-Pedoe et al. 
1999). The prognosis of patients with AMI can considerably be improved with 
the timely use of efficient modern management strategies. This includes the use 
of coronary angiography and percutaneous coronary intervention (PCI), which 
have revolutionized management and outcomes in these high-risk patients. 
In Eastern Europe mortality from CAD has steadily been decreasing over the 
last decade. Still, mortality rates remain higher than they are in the Western 
high-income countries (Eurostat 2012). Furthermore, Estonia has reported one 
of the highest rates of CAD mortality in Europe. The data from the Euro Heart 
mapping project in 2009 (www.eurekalert.org) revealed that Estonia has one of 
the highest rates of death from cardiovascular diseases among men and women 
under 65 years of age. 
The health care system of Estonia has undergone considerable changes 
during the last decade. Much effort has been made to improve the quality of 
care for AMI patients through better application of recommendations in the 
management guidelines. A study conducted in 2001 (Ainla et al. 2006) showed 
important disparities in the management and outcomes of patients with AMI in 
tertiary and secondary care hospitals in Estonia. The use of PCI was low and 
only one fourth of the patients in specialized hospitals were treated with this 
management method. Therefore, one of the main priorities has been to increase 
access to PCI and to enable more ST-segment elevation AMI (STEMI) patients 
to receive timely reperfusion therapy, including primary PCI. Nevertheless, 
owing to the small population of 1.3 million, as well as to technical require-
ments and economical reasons, PCI facilities are available only in specialized 
hospitals. Although several studies have clearly demonstrated the association 
between the availability of on-site PCI facilities and their use in the mana-
gement of patients with AMI, its impact on short- and long-term outcomes is 
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conflicting and prone to regional variations. There are currently little data in 
Estonia comparing the changes in the management, including selection for PCI, 
and outcomes of AMI patients first admitted to hospitals with different level of 
care and unequal availability of PCI. Furthermore, as access to personalized 
data has been restricted for legal reasons, research on the long-term fatal and 
non-fatal outcomes of AMI patients has been halted for several years. Yet, such 
information is crucial to both the public and to health care professionals when 
aiming to offer equitable healthcare services to all patients in Estonia in a 
setting of limited health care resources. 
There is urgent need for data on the management and outcomes of AMI in 
the real life setting. The concept of modern evidence-based care is mostly based 
on the results derived from randomized controlled studies (Sackett et al. 1996; 
Chalmers 1998). Yet these include younger patients with less co-morbidities, 
more often of the male sex (Hannan 2008). However, in the clinical practice the 
management and outcomes of AMI are challenged by the aging of the 
population, the higher rates of female patients, and the increasing presence of 
co-morbidities such as diabetes mellitus (DM) (Alexander et al. 2005; Koek et 
al. 2007). Indeed, the prevalence of DM in the population is rapidly rising, 
especially among women (Wild et al. 2004; International Diabetes Federation, 
Diabetes Atlas 2011). At the same time, data about the effect of DM on the sex-
specific outcomes of patients with AMI are conflicting (Hyvarinen et al. 2009). 
The current study was undertaken to evaluate the changes in the baseline 
characteristics, management and outcomes of patients with AMI in Estonia 
during the last decade as well as to study the long-term outcomes after PCI in 
different AMI patient subgroups. 
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2. REVIEW OF THE LITERATURE 
2.1. Pathogenesis of AMI 
AMI represents a life-threatening manifestation of atherosclerosis. It is usually 
precipitated by acute thrombosis that is induced by a ruptured or eroded athero-
sclerotic plaque. This will lead to sudden and critical reduction in the blood 
flow in the coronary arteries resulting in the death of cardiomyocytes. In rare 
cases AMI may have a non-atherosclerotic etiology such as arteritis, trauma, 
dissection, thrombo-embolism, congenital anomalies, and complications of 
coronary angiography. The complete necrosis of all myocardial cells at risk 
requires at least 4 h to 6 h or longer, depending on the presence of collateral 
blood flow into the ischemic zone, persistent or intermittent coronary artery 
occlusion and the sensitivity of the myocytes (Libby et al. 2007).  
 
 
2.2. Definition of AMI 
In 1979 the WHO defined AMI by a combination of two of the three characte-
ristics: typical symptoms, enzyme rise and a typical electrocardiogram (ECG) 
pattern involving development of Q waves. However, progress in the develop-
ment of more sensitive and specific biomarkers and precise imaging techniques 
(echocardiogarphy, radionuclide imaging, magnetic resonance imaging, compu-
ted tomography) has enabled to detect smaller amounts of myocardial necrosis.  
In 2000, the Joint European Society of Cardiology/ American College of 
Cardiology Committee published the consensus document regarding the rede-
finition of myocardial infarction (Alpert et al. 2000). This document implied 
that any necrosis in the setting of myocardial ischaemia should be labelled as 
AMI and the use of cardiac troponins (Troponin T or Troponin I) was intro-
duced into the clinical practice.  
The criteria for an AMI were the following: 
1) Typical rise and gradual fall of troponin and/or creatine kinase MB with at 
least one of the following:  
a. ischaemic symptoms;  
b. changes on the ECG indicative of ischemia (ST-segment elevation or 
depression);  
c. development of pathologic Q-waves on the ECG; or 
d. coronary artery intervention. 
2) Pathological findings of an AMI.  
 
By 2007, the new generation of troponin assays enabled a more sensitive and 
more specific detection of the increase in the cardiac troponin levels. This resulted 
in the launch of the universal definition of myocardial infarction by the Joint 
European Society of Cardiology/ American College of Cardiology/ American 
Heart Association/ World Heart Federation Task Force (Thygesen et al. 2007). 
Additionally, the document recognized the importance of imaging techniques in 
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the diagnosis of AMI. The new diagnosis guidelines were adapted in Estonia in 
June 2010 (Eesti Kardioloogide Selts, Eesti Laborimeditsiini Ühing 2010). 
The third universal definition of AMI (Thygesen et al.), released in august 
2012, recognizes that very small amounts of myocardial injury or necrosis can 
be detected with the help of biochemical markers and/or imaging. The latest 
generation, high sensitivity troponin assays, enable the detection of myocardial 
damage already within the first hours of the onset of AMI (Hamm et al. 2011). 
These assays have high sensitivity with the cost of lower specificity, making 
recognition of ischemic symptoms in the diagnosis of AMI even more important 
(Keller et al. 2011).  
 
Subtypes of AMI 
The major subdivision of AMI is based on the findings in the ECG: (1) 
persistent ST-segment elevation/ new left bundle branch block (STEMI/LBBB 
AMI) or (2) non-ST-segment elevation (NSTEMI). The underlying patho-
genesis in these two entities is different. The thrombus is fibrin rich and comp-
letely occlusive in STEMI, whereas it is platelet-rich and partially or inter-
mittently occlusive in NSTEMI (Libby et al. 2007).  
 
 
2.3. Epidemiology of AMI 
Information on AMI incidence rates is used to estimate the burden of CAD 
within and across populations. It also gives useful data regarding the impact of 
developments in the AMI management in time, especially if data are collected 
in a manner distinguishing between new and recurrent events in a patient. 
Hospitalization for AMI is often used as a proxy to study the trends in AMI 
incidence. However, their interpretation is often challenging given the reliance 
on hospital administrative systems.  
During the last few decades the Western high-income countries have 
observed detrimental trends in the cardiovascular risk factor profile among the 
populations, including less physical activity, more obesity and DM, and aging 
of the population (Danaei et al. 2011;  Farzadfar et al. 2011; Finucane et al. 
2011). At the same time a range of lifestyle, medical and interventional 
strategies for primary and secondary prevention of AMI have been adopted.  
Starting from the 1950ies, several landmark studies in the USA and Europe 
have observed declines in the rates of hospitalization for AMI (Rosen et al. 
2000; McGovern et al. 2001; Messner et al. 2003; Fox et al. 2004; Floyd et al. 
2009; Myerson et al. 2009; Parikh et al. 2009; Yang et al. 2011). The rates 
decreased modestly or in some countries even increased until the end of the 
1990 and thereafter started to decrease substantially (Yeh et al. 2010; Fang et 
al. 2010). Also the rates of out-of-hospital deaths from AMI have declined 
(McGovern et al. 2001; Abildstrom et al. 2003; Lundblad et al. 2008).  
The interpretation of epidemiological trends is challenged by the intro-
duction of cardiac biomarkers of varying sensitivity and specificity for detection 
of AMI over time. Indeed, the reported hospitalization rate of AMI increased 
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slightly after the diagnostic criteria for AMI were introduced in 2000 (Ferguson 
et al. 2002). Nevertheless, it should be noted that the rates of AMI diagnosed by 
ECG have declined by 50%, whereas the rates of AMI diagnosed by cardiac 
markers have doubled (Rogers et al. 2008). 
 
Epidemiology of AMI subtypes 
Since the middle of the 1990, the proportion of patients with NSTEMI has 
increased from approximately 60% to 75% (Yeh et al. 2010; Jernberg et al. 
2010;  Floyd et al. 2009). The changes have been more pronounced since 2000 
(Ferguson et al. 2002; Yeh et al. 2010) when the new definition document of 
AMI was issued (Alpert et al. 2000).  However, it is considered that the higher 
rates of NSTEMI are due to the aging of the population, greater prevalence of 
co-morbidities, and substantial improvements in primary prevention efforts such 
as management of dyslipidemia and hypertension, that might lessen ischemia 
and retard platelet aggregation (Myerson et al. 2009). 
 
Epidemiology of AMI according to sex 
The decrease in the age-standardized rate for hospitalizations for AMI has been 
less pronounced in women than in men (Rosen et al. 2000; Roger et al. 2002; 
Messner et al. 2003; Yang et al. 2011). Interestingly, among women the events 
are declining mainly for recurrent AMI, whereas both first and recurrent AMIs 
decline among men (Lundblad et al. 2008).  
 
Epidemiology of AMI in Estonia 
In Estonia, recent research data on the incidence of AMI is available from the 
Tallinn AMI Registry, that included residents aged 35–64 years during two time 
periods, 1991–1997 and 2003–2005 (Laks et al. 2012). When analyzed annually, 
the rates of AMI increased from 1991 to 1993 in both sexes. Thereafter the 
incidence of the first AMI started to decline, and this trend continued until 2005. 
Hospitalization rates for AMI [main diagnosis code I21–I22 according to the 
International Statistical Classification of Diseases and Related Health Problems 
10th revision (ICD-10)] for the whole of Estonia during 1998–2010 are available 
from the National Institute for Health and Development’s Health Statistics and 
Health Research Database (2012). According to this administrative database the 
rate of hospitalization for AMI show an increase during the last decade. The 
validity of this database has not been established and the trends have not been 
studied further.  
 
2.4. Baseline characteristics of patients with AMI  
Several studies in the USA and Europe have demonstrated the changing base-
line characteristics of hospitalized AMI patients over the last decades. 
Collectively these studies show that patients with AMI have become 
significantly older – the proportion of patients over 75 years of age has risen to 
approximately 40% and those over 85 years to 20%. This is probably reflective 
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of the aging of the Western population, as well as of the increasing adoption of 
healthy lifestyle practices and other primary preventive modalities in the 
general population and in various at-risk groups. 
The AMI patients are now more likely to be obese (Body Mass Index  
≥ 30 kg/m2, 20–36%), have dyslipidemia (42–49%), have a prior history of DM 
(23–40%), hypertension (60–75%), stroke (7–9%), chronic heart failure (20–
30%), and peripheral vascular disease (7–21%). This likely mirrors the growing 
epidemics of obesity and glycometabolic disturbances. It is also possible that 
the redefinition of hypertension and hypercholesterolemia over time has 
resulted in an increase in the rates of these diseases. Particularly striking is the 
increase in the prevalence of prior AMI (18–34%), PCI (8–17%), and coronary 
artery bypass grafting (CABG; 4–13%). The rate for current smokers has 
decreased to about 22–33% (Goldberg et al. 2004; Kuch et al. 2008; Floyd et al. 
2009; Rogers et al. 2008;  Krumholz et al. 2009; Goodman et al. 2009; Nauta et 
al. 2011; Gierlotka et al. 2012).  
Patients with either cardiac arrest before admission or with significant hemo-
dynamic disorders (pulmonary edema and cardiogenic shock) on admission 
have become significantly less frequent (Isaksson et al. 2008). The duration of 
pre-hospital delay after the onset of AMI has remained essentially unchanged 
over the two last decades (Goldberg et al. 2004; Isaksson et al. 2008; Saczynski 
et al. 2008; Goldberg et al. 2009; Floyd et al. 2009; Fang et al. 2010;  Nguyen 
et al. 2010a;  Nguyen et al. 2010b).  
 
Baseline characteristics of AMI subtypes 
Compared to STEMI patients, those with NSTEMI are older, show higher rates 
of co-morbidities (Maier et al. 2008; Nauta et al. 2011; McManus et al. 2011), 
and have more extensive coronary artery disease (Abbott et al. 2007). Patients 
with NSTEMI are nearly twice more likely to present without chest pain than 
patients with STEMI (Canto et al. 2012). At the same time, patients with 
STEMI have more frequently pre-hospital cardiac arrest and acute heart failure 
at presentation (Xu et al. 2011). 
 
Baseline characteristics of AMI according to sex 
The proportion of women has increased and they comprise now over a third of 
the AMI population (Rogers et al. 2008; Krumholz et al. 2009; Goodman et al. 
2009; Nauta et al. 2011). The reason for the increase in the proportion of 
females to males, especially among patients with NSTEMI, may be related to 
the increasing emphasis on the clinical recognition of acute coronary syndromes 
in women (Mosca et al. 1997). Alarmingly, recent data suggest that the pro-
portion of younger women presenting with STEMI may be increasing (Puymirat 
et al. 2012). 
When studying sex differences in baseline characterisics it can be seen that 
women are older with a higher prevalence of hypertension, chronic heart failure, 
and DM; but they are also less likely to have a history of prior AMI or to be 
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smokers (Bakler et al. 2004; Jneid et al. 2008; Tatu-Chitoiu et al. 2009; Dey et 
al. 2009).  
Upon presentation to hospitals a lower proportion of women than men have 
typical chest pain symptoms (approximately 55% vs 70%; Isaksson et al. 2008; 
Coventry et al. 2011; Canto et al. 2012). There seems to be an interaction 
between age and sex with typical symptoms at presentation, with a larger sex 
difference in younger than older patients, which becomes attenuated with 
advancing age (Canto et al. 2012). A greater proportion of women than men 
present with congestive heart failure at the time of hospital admission (Tatu-
Chitoiu et al. 2009).  
 
 
2.5. Management of patients with AMI  
The overall goal of the management of AMI is to reduce morbidity, to prevent 
complications, including death, and to enable the patients to return to their daily 
activities as soon as possible. Numerous randomized clinical trials conducted in 
recent decades have led to the development of effective management strategies 
for AMI. On the basis of these trials, detailed management guidelines for 
STEMI and NSTEMI have been compiled (Bertrand et al. 2002; Braunwald et 
al. 2002; Van de Werf et al. 2003; Antman et al. 2004; Bassand et al. 2007; 
Van de Werf et al. 2008; Wijns et al. 2010; Hamm et al. 2011; Steg et al. 
2012).  
2.5.1. Medical management  
Anti-platelet therapy 
Platelet activation and aggregation play a major role in the mechanism of 
thrombosis and therefore are the key therapeutic targets in the management of 
AMI. Platelets can be inhibited by three classes of drugs, each of which has a 
distinct mechanism of action. 
Acetyl salicylic acid (ASA) is an established drug in the treatment of AMI 
since the Second International Study of Infarct Survival (ISIS-2 Collaborative 
Group 1988). It acts through irreversible inactivation of cyclooxygenase-1, thus 
inhibiting thromboxane A2 formation and, consequently inhibiting permanently 
the function of platelets. According to the current guidelines (Hamm et al. 
2011; Steg et al. 2012), in suspicion of an AMI, ASA should be given as soon 
as possible in the absence of contraindications like active gastrointestinal 
bleeding, known clotting disorders, hypersensitivity, and severe hepatic disease. 
In the long-term secondary prevention of AMI, ASA reduces the risk of serious 
cardiovascular events by a quarter (Baigent et al. 2009). 
In addition to the effects of ASA, other complementary platelet aggregation 
pathways must be inhibited to ensure effective treatment and prevention of 
coronary thrombosis. The antagonists of the P2Y12 receptor, such as thieno-
pyridines, have proven to be major therapeutic tools in the treatment of AMI. 
The thienopyridine prodrugs such as clopidogrel and prasugrel are actively 
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biotransformed into molecules that bind irreversibly to the P2Y12 receptor. A 
newer class of drug on the market is the pyrimidine derivative ticagrelor, which 
without biotransformation binds reversibly to the P2Y12 receptor. Over the 
years, as more research data has emerged, the use of P2Y12 receptor inhibitors 
has become more prevalent. According to the current AMI guidelines (Hamm et 
al. 2011; Steg et al. 2012), a P2Y12 receptor inhibitor should be added to ASA 
as soon as possible and maintained over 12 months, unless there are 
contraindications such as excessive risk of bleeding.  
A third group of antiplatelet drugs that target the final common pathway of 
platelet aggregation by inhibiting fibrinogen binding to platelets are the glyco-
protein receptor IIb/IIIa antagonists which are administered intravenously and 
only during hospitalization. The use of these drugs on top of ASA and a P2Y12 
receptor inhibitors is reserved for high-risk patients when the the risk of 
bleeding is low (Hamm et al. 2011; Steg et al. 2012).  
 
Anticoagulants 
Anticoagulation is recommended for all patients in addition to antiplatelet 
therapy (Hamm et al. 2011; Steg et al. 2012). The choice of combination of 
antiplatelet agents and anticoagulants should be made in relation to the risk of 
ischemic and bleeding events. Newer anticoagulat regimes aim at decreasing 
thromboembolic events without increasing the risk of bleeding complications.  
Anticoagulants act through reducing thrombus-related events by inhibiting 
thrombin generation and activity. Currently the there are several indirect and 
direct inhibitors of coagulation available. Among the indirect inhibitors there 
are the older drugs, unfractionated heparin (UFH) and low-molecular-weight 
heparins (LMWH) that bind to antithrombin III and enhance inactivation of 
factors Xa and thrombin. As compared to UFH, LMWH has a predictable 
pharmacokinetic profile, high bioavailability, and long plasma half-life, all of 
which result in effective levels of anticoagulant activity after subcutaneous 
administration without the need of constant laboratory monitoring. Fonda-
parinux, a relatively newer drug, is the only selective factor Xa inhibitor 
available for clinical use. Fondaparinux is easy to use, is not associated with the 
risk of heparin-associated thrombocytopenia and has currently one of the most 
favourable efficacy-safety profiles among the anticoagulants on the market. 
Bivalirudin, belonging also to the newer drugs, is at the moment the only 
direct inhibitor of coagulation that has proven to be efficacious in the treatment 
of AMI. It binds directly to thrombin and thereby inhibits the thrombin-induced 
conversion of fibrinogen to fibrin.  
 
Beta-blockers  
Beta-blockers competitively inhibit the myocardial effects of circulating 
catecholamines and reduce myocardial oxygen consumption by lowering heart 
rate, blood pressure, and contractility. The evidence for the use of beta-blockers 
in AMI is mainly derived from older trials conducted before the reperfusion era 
(Freemantle et al. 1999). In the absence of contraindications, beta-blockers are 
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recommended in all AMI patients as secondary prevention, especially if the left 
ventricular function is reduced or if there have been signs of heart failure 
(Hamm et al. 2011; Steg et al. 2012). However, in the acute phase they increase 
the risk of cardiogenic shock (Chen et al. 2005) and should rather be used in 
patients in a stable hemodynamic condition (Killip class < III) with hyper-
tension and/or tachycardia.  
 
Angiotensin-converting enzyme inhibitors/ angiotensin II receptor blockers  
Angiotensin-converting enzyme inhibitors/ angiotensin II receptor blockers 
(ACEIs/ARBs) reduce infarct size, limit ventricular remodeling, and improve 
survival after AMI (Dagenais et al. 2006; Danchin et al. 2006).  Over the years 
their rutine use has increased (Marguils et al. 2011) and the current guidelines 
state that in the absence of contraindications, they should be started already 
within the first 24 hours of hospitalization, especially in patients with evidence 
of heart failure, left ventricular systolic dysfunction, diabetes, hypertension, or 
an anterior infarct (Hamm et al. 2011; Steg et al. 2012). 
 
Statins 
In the 1950s and 1960s, it became apparent that dyslipidemia was a major 
cardiovascular risk factor. This is targeted by statins by inhibiting the HMG-
CoA reductase which acts as a central enzme in the biosynthetic pathway of 
cholesterol. Since the first studies, conducted at the end of the 1980s (Tobert 
2003), the use of statins has increased for the secondary prevention of AMI 
(Marguils et al. 2011). They are currently recommended to be initiated in high 
dose early after admission in all AMI patients without contraindication or 
history of intolerance, regardless of initial cholesterol values (Hamm et al. 
2011; Steg et al. 2012). 
 
Nitrates 
The therapeutic benefit of nitrates is related to their venodilator effects that lead 
to a decrease in the myocardial preload and left ventricular end-diastolic 
volume, resulting in a decrease in myocardial oxygen consumption. In addition, 
nitrates dilate normal as well as atherosclerotic coronary arteries and increase 
coronary collateral flow (Libby et al. 2008). The routine use of nitrates has not 
proven to reduce mortality (Fourth International Study of Infarct Survival 
Collaborative Group 1995). 
 
 
2.5.2. Invasive management 
Coronary angiography and revascularization  
Coronary angiography defines coronary anatomy and provides valuable 
decision-facilitating information for further invasive or non-invasive manage-
ment strategies and enables more precise risk stratification. The current guide-
lines recommend coronary angiography and, if applicable, revascularization 
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(PCI and/or CABG) for all AMI patients in the absence of contraindications 
(e.g. risk of bleeding, patient does not consent) (Wijns et al. 2010; Hamm et al. 
2011; Steg et al. 2012).  
Since Andreas Grüntzig performed the first intraoperative balloon angio-
plasty on the human heart in 1979 (Grüntzig et Kumpe 1979) the method of PCI 
has witnessed significant technological advances, in particular, the use of drug-
eluting stents (DES) and it has become a  vital component in the management of 
AMI patients. The possible complications of PCI for AMI include death (3.5%), 
non-fatal AMI (2.0%), major bleeding (1.5%), and non-fatal stroke (0.5%; 
Wang et al. 2011).  
 
Revascularization for NSTEMI 
In NSTEMI the timing of angiography (urgent <2 h, early <24 h, or late <72 h) 
depends on the clinical presentation and cardiovascular risk of the patient. The 
revascularization strategy (PCI and/or CABG) should be based on the clinical 
status as well as the disease severity, i.e. distribution and coronary lesions and 
their characteristics (Wijns et al. 2010; Hamm et al. 2011). 
 
Reperfusion and revascularization for STEMI 
In STEMI myocardial necrosis caused by complete coronary artery occlusion 
begins to develop after 15–30 min of severe ischemia (no forward or collateral 
flow) and progresses from the subendocardium to the subepicardium in a time-
dependent fashion (Libby et al. 2007). So the patients should receive reper-
fusion as soon as possible to save the myocardium at risk from undergoing 
necrosis. 
Reperfusion therapy for STEMI is indicated in all patients with a history of 
chest pain/discomfort of <12 h and with persistent ST-segment elevation or 
(presumed) new left bundle-branch block (Steg et al. 2012). In case of evidence 
of ongoing ischemia, even if symptoms may have started >12 h earlier, reper-
fusion may be beneficial. 
As randomized controlled trials and meta-analyses have shown the superio-
rity of primary PCI over in-hospital thrombolysis through more effective 
restoration of vessel patency, less re-occlusion, improved residual left ventri-
cular function, and better clinical outcome, it has become the treatment of 
choice if it can be performed in a timely manner (Zijlstra et al. 1999; Keeley et 
al. 2003; Widimsky et al. 2003; Widimsky et al. 2007).  
The current European STEMI guideline emphasizes the importance of a well 
existing national STEMI network between hospitals with various levels of 
technology, connected by an efficient ambulance (or helicopter) service (Figure 
1) (Steg et al. 2012). It has been associated with diminished patient delay to 
reperfusion and could reduce mortality due to out-of-hospital cardiac arrest 
(Taglieri et al. 2011). Electronic transmission of a pre-hospital 12-lead ECG in 
chest pain patients has proven to reduce time to PCI (Sejersten et al. 2008) and 
is an established tool to accelerate correct and timely management (Bradley et 
al. 2007). Unfortunately, the possibility of pre-hospital electronic transmission 
of ECG has not been established in Estonia yet. 
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While the patient-related pre-hospital delays have changed little over the 
years, the door-to-needle times for thrombolysis and door-to-balloon times for 
primary PCI have been reduced considerably (Gibson et al. 2008; Schiele et al. 
2010;  Flynn et al. 2010; Towae et al. 2011). 
 
 
 
Figure 1. Prehospital and in-hospital management, and reperfusion strategies within  
24 h of FMC (modified from Steg et al. 2012)  
FMC – first medical contact; STEMI – ST-segment elevation myocardial infarction; 
PCI – percutaneous coronary intervention  
 
 
2.5.3. Treatment quality indicators 
With reference to the performance measures presented in the AMI guidelines, 
several countries have developed quality indicators for measuring the manage-
ment and outcomes of AMI (Spertus et al. 2005; Tu et al. 2008). An illustrative 
list of the most commonly used quality indicators for in-hospital management is 
presented in Table 1.  
 
 
22 
Table 1. In-hospital process-of-care, outcome and system indicators* for acute myo-
cardial infarction 
 
Pharmacologic process-of-care indicators 
− Acetyl salicylic acid prescribed during hospitalization and at discharge 
− P2Y12 blockers prescribed during hospitalization and at discharge − Beta-blockers prescribed during hospitalization and at discharge 
− Angiotensin-converting enzyme inhibitors/ angiotensin II receptor blockers 
prescribed during hospitalization and at discharge 
− Statin prescribed during hospitalization and at discharge  
− Use of low-molecular-weight heparin /heparin/fondaparinux during 
hospitalization 
− Thrombolysis within 30 minutes after hospital arrival 
Non-pharmacologic process-of-care indicators  
− Electrocardiogram within 10 minutes after hospital arrival  
− Primary percutaneous coronary intervention within 90 minutes after hospital 
arrival  
− Reperfusion therapy in eligible patients with ST-segment elevation myocardial 
infarction  
− Coronary angiography and percutaneous coronary intervention done or planned 
for non-ST-segment elevation myocardial infarction  
− Risk stratification (i.e., coronary angiography, exercise stress testing, perfusion 
imaging or stress echocardiography)  
− Assessment of left ventricular function  
− Smoking cessation advice, counseling or therapy during hospital stay  
− Referral to cardiac rehabilitation 
Outcome indicator 
− In-hospital mortality 
*These indicators are measurable from chart review 
 
 
The idea of these indicators is to enhance the application of evidence-based care 
in real clinical practice and by doing so to improve the prognosis of patients 
with AMI. When most registries and quality of care improvement programs 
only focus on in-hospital management then there are some exceptions like the 
SWEDEHEART (Swedish Web-system for Enhancement and Development of 
Evidence-based care in Heart disease Evaluated According to Recommended 
Therapies; Jernberg et al. 2010), which allow also to gather data during follow-
up. A corresponding illustrative list can be found in Table 2.  
The above quality indicators are used nationally and internationally for 
benchmarking hospitals and for suggesting further improvements in AMI 
management. The concept and composition of the quality indicators have been a 
matter of considerable debate over the years. Furthermore, a fair inter-hospital 
comparison requires high-quality data and sophisticated data analysis, including 
proper adjustment for confounding factors. This is often hard to achieve as 
administrative databases are usually not fit to meet such high demands. It has 
been argued whether inter-hospital comparisons of in-hospital AMI mortality 
can really serve the purpose of fostering quality improvement (Aelvoet et al. 
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2010). Nevertheless, as the Get With the Guidelines-Coronary Artery Disease 
quality improvement program in the USA showed, participation in such a 
program significantly improves the management and outcomes of AMI patients 
(Xian et al. 2010; Peterson et al. 2006).  
 
 
Table 2. Out-of-hospital process-of-care and outcome indicators* for acute myocardial 
infarction 
 
Pharmacologic process-of-care indicators
− Prescription for beta-blocker filled within 30 days after discharge 
− Adherence to beta-blocker therapy 1 year after discharge 
− Prescription for angiotensin-converting enzyme inhibitor/ angiotensin II receptor 
blocker filled within 30 days after discharge 
− Adherence to angiotensin-converting enzyme inhibitor/ angiotensin II receptor 
blocker therapy 1 year after discharge 
− Prescription for statin filled within 30 days after discharge 
− Adherence to statin therapy 1 year after discharge 
Non-pharmacologic process-of-care indicators
− Physician visit within 4 weeks of discharge 
− Median waiting time (in days) for coronary angiography after myocardial 
− infarction 
− Median waiting time (in days) for percutaneous coronary intervention after 
 myocardial infarction 
− Median waiting time (in days) for coronary artery bypass graft surgery after 
 myocardial infarction 
Outcome indicators 
− 30-day mortality 
− 1-year mortality 
− 30-day readmission rate because of acute myocardial infarction 
− 1-year readmission rate because of acute myocardial infarction 
− 30-day readmission rate because of congestive heart failure 
− 1-year readmission rate because of congestive heart failure 
− 30-day readmission rate because of unstable angina 
− 1-year readmission rate because of unstable angina 
− 30-day need for revascularization 
− 1-year need for revascularization 
*These indicators are measurable using administrative data 
 
 
Application of guideline recommendations 
Implementation of evidence-based management strategies into clinical practice 
for treatment of AMI has increased considerably over time (McGovern et al. 
2001; Goldberg et al. 2004;  Gislason et al. 2005; Kuch et al. 2008; Maier et al. 
2008; Floyd et al. 2009;  Janion et al. 2009; Tatu-Chitoiu et al. 2009; Goodman 
et al. 2009; Jernberg et al. 2011; Nauta et al. 2011; Aliprandi-Costa et al. 2011; 
Gierlotka et al. 2012).  
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Such progress has been evident in all age groups, including the elderly 
(Schiele et al. 2009; Nauta et al. 2012). Still, although adherence to guidelines 
has been shown to be associated with improved outcomes, their implementation 
remains sub-optimal. As demonstrated by the Get With the Guidelines-Coro-
nary Artery Disease quality improvement program (Medina et al. 2011) im-
portant age-related gaps remain in management and outcomes, suggesting 
opportunities to improve prognosis in high-risk populations. There appears to be 
a “risk-management paradox” wherein higher-risk patients are less likely to 
receive guideline recommended therapies (Motivala et al. 2011). Previous 
studies have also demonstrated that women are treated less aggressively and 
less invasively than men (Hvelplund et al. 2010).  
As not all hospitals have access to coronary angiography and revascula-
rization facilities, the rate of patients undergoing these management options 
varies across hospitals and is the underlying reason for inequalities in appli-
cation of management strategies (Luthi et al. 2005;  Ainla et al. 2006; Radova-
novic et al. 2010; Widimsky et al. 2010). In addition, adherence to recommen-
dations in the AMI guidelines has been shown to be higher in academic 
hospitals compared to their non-academic counterparts (Belle et al. 2012). 
 
Adherence to secondary prevention of AMI 
When the in-hospital mortality of AMI has decreased significantly during the 
last decades, then the decrease in long-term mortality is less pronounced (Grau 
et al. 2012). This indicates the importance of lifelong adherence to the secon-
dary prevention strategies of AMI. Optimal medical therapy for the secondary 
prevention of AMI over one year has been associated with a significantly lower 
mortality of patients with AMI in clinical practice (Bramlage et al. 2010). Total 
mortality is reduced by 74% in patients receiving optimal medical therapy 
versus patients receiving one or no drug.  
However, optimal medical therapy is provided to less than half of eligible 
patients. Eagle et al. (2004) found that among the patients for whom key 
evidence-based medications at discharge was prescribed, 8% to 20% were no 
longer taking their medication after 6 months. A recent study concerning drug 
utilization in different age and gender groups following AMI in Estonia found 
that only 40% were treated by combinations of beta-blockers, ACEIs/ ARBs  
and statins at 1-year follow-up (Marandi et al. 2010).  
The reasons for noncompliance are complex and depend on the characte-
ristics of patients, physicians, hospitals and communities. Clearly the first key 
to adherence to the secondary prevention methods is initiation of medications 
already during hospitalization for AMI. Interestingly, patients who receive care 
from non-cardiologists and physicians with many years of experience tend to 
receive substantially less evidence-based drug therapies after discharge (Austin 
et al. 2008). There is a wide inter-hospital and inter-physician variation in 
initiating drugs, the most pronounced being for newer drugs like statins 
(Margulis et al. 2011). Furthermore, there seems to be inter-drug variation in 
patient adherence as well (Sorensen et al. 2008). 
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2.5.4. Overview of the types of hospitals treating patients with  
AMI in Estonia 
In 2001, the management of AMI patients was shared among 27 Estonian 
hospitals with a different number of beds. There were 2 tertiary care hospitals, 
which had the availability of PCI, but only during working hours (Fig. 2). In the 
secondary care hospitals the number of annual AMI cases ranged from 7 to 165 
and the attending physicians were mainly anesthesiologists or internists and in 
some hospitals also cardiologists. None of the secondary care hospitals had 
angiography or PCI facilities.  
By 2007, as a result of changes in the hospital network, only 20 hospitals 
admitted AMI patients. The 2 tertiary hospitals had PCI availability 24 hours 7 
days a week. In the secondary care hospitals the number of annual AMI cases 
ranged from 16 to 267 and one hospital had on-site PCI facilities but only 
during working hours. In 2012, there are 2 tertiary care PCI-capable hospitals 
operating 24 hours 7 days a week and 3 secondary care hospitals with onsite 
PCI (one of them operating 24/7). 
 
 
 
Figure 2. Location of hospitals with on-site PCI facilities and longest transfer distances 
between hospitals in Estonia in 2001 and 2007 
PCI – percutaneous coronary intervention available during working hours 
PCI 24/7 – percutaneous coronary intervention available 24 hours a day 7 days a week 
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2.6. Outcomes of patients with AMI 
Community studies have shown that the overall case fatality rate for patients 
with presumed AMI or acute coronary syndrome in the first month can be as 
high as 50%, and out of these deaths about half occur within the first two hours 
(Tunstall-Pedoe et al. 1999).  
This high initial mortality has altered little over the last years in contrast to 
in-hospital mortality (Goldberg et al. 2006). Prior to the introduction of coro-
nary care units in the 1960s, the in-hospital mortality seems to have averaged 
between 25 and 30%. In the pre-reperfusion era, in the mid-1980s, the in-
hospital mortality was approximately 16% (Sarmento-Leite et al. 2001; Mukau 
2011). With the widespread use of coronary interventions, thrombolytic agents, 
antithrombotic therapy, and secondary prevention, the overall 1-month morta-
lity has since been reduced to 4–6%, at least in patients who have participated in 
the latest randomized large-scale trials and qualified for thrombolysis and/or 
coronary interventions (De Boer et al. 2010). However, mortality rates in 
registry studies are much higher, suggesting that the patients included in rando-
mized controlled trials are at a lower risk when compared with those in obser-
vational studies (Fox et al. 2006).  
The decline in the short- and long-term mortality of patients with AMI has 
been demonstrated by several large registry studies in the USA and Europe 
since the 1950 (Parikh et al. 2009; Floyd et al. 2009; Movahed et al. 2011; 
Hardoon et al. 2011; Smolina et al. 2012), including the National Registry of 
Myocardial Infarction (NRMI; Rogers et al. 2008). The improved prognosis can 
be assigned to all AMI patient subgroups independently of sex, age, and co-
morbidity (Schmidt et al. 2012). The age- and sex-adjusted 30-day, 1-year, and 
5-year AMI mortality has declined by approximately 60%. The Register of 
Information and Knowledge about Swedish Heart Intensive Care Admission 
showed that for STEMI the estimated in-hospital, 30-day and 1-year mortality 
decreased during 1996–2007 from 12.5% to 7.2%; from 15.0% to 8.6%; and 
from 21.0% to 13.3%, respectively (Jernberg et al. 2011). The improvements in 
survival tended to be greater in the latter part of this 12-year period. This 
probably reflects the advances in the coronary reperfusion techniques, develop-
ment of more effective adjunctive cardiac therapies, and increased utilization of 
these management modalities.  
As increasingly more AMI patients survive during hospitalization, more 
attention is paid to non-fatal outcomes during hospitalization and follow-up. 
The Global Registry of Acute Coronary Events (GRACE) showed that during 
hospitalization for AMI the rates of cardiogenic shock, congestive heart failure 
and pulmonary edema have declined both in STEMI and NSTEMI populations 
(Fox et al. 2007). Still, recurrent ischemic symptoms occured approximately in 
20%, heart failure in 13%, re-infarction in 11%, and major bleeding and stroke 
in less than 2% of the patients (Goodman et al. 2009). At 6-months follow-up 
after hospitalization for AMI, 18% were re-admitted for chronic heart failure, 
9% underwent PCI and 6% CABG (Goldberg et al. 2004).  
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AMI subtype specific outcomes  
The proportion of patients presenting with NSTEMI is increasing. Compared to 
STEMI, patients who experience a NSTEMI have lower 30-day mortality 
(Armstrong et al. 1998). However, the 6-month mortality rates are similar for 
STEMI and NSTEMI patients (Volmink et al. 1998). There are thought to be 
several reasons for this. Patients with STEMI have more frequently pre-hospital 
cardiac arrest and acute heart failure at presentation, which has a negative im-
pact on the outcomes. Additionally, lower ischemic preconditioning and larger 
infarct sizes in patients with STEMI have been described (Xu et al. 2011). In 
contrast, higher age and higher prevalence of co-morbidities increase the rate of 
mortality for NSTEMI during long-term follow-up. In addition, NSTEMI 
patients often seem to be undertreated compared to STEMI patients (Roe et al. 
2005). 
The shift in the proportion of AMI subtypes also implies that hospitalized 
AMI cases have smaller infarct sizes (Xu et al. 2011). Furthermore, as less 
patients die during hospitalization, more patients develop chronic heart failure 
afterwards (Ezekowitz et al. 2009). This increases the mortality risk during the 
long-term follow-up and highlights the importance of life-long secondary 
prevention for AMI.  
 
Sex-specific outcomes of AMI 
Despite the overall reduction in the death rate due to CAD over the several 
recent decades, the rate of the decline is less pronounced for women than for 
men (Heart Disease and Stroke Statistics update 2011). Also the mortality rates 
after AMI have decreased less for women than for men (Grau et al. 2012). 
Women suffer acute coronary syndromes approximately ten years later than 
men and have a higher cardiovascular risk factor burden at the time of pre-
sentation (Coppieters, et al. 2011). However, the increased risk of mortality 
among women with AMI compared to men is not consistently eliminated after 
adjustments for co-morbidities  (Chandra et al. 1998; Vaccarino et al. 1999;  
Jneid et al. 2008; Dey et al. 2009). Many studies have attributed this finding to 
difficulties in recognizing symptoms, delay in presentation to the hospital and 
diagnosis, or under-use of recommended diagnostic tests and therapies in 
women (Jneid et al. 2008;  Dey et al. 2009; Bugiardini et al. 2011; Canto et al. 
2012; Ravn-Fischer et al. 2012). For instance, women with AMI are referred 
less often for invasive diagnostic procedures and thus they undergo percuta-
neous or surgical revascularization less frequently than men (Harrold et al. 
2003;  Haglund et al. 2004; Vikman et al. 2007; Lee et al. 2008; Peterson et al. 
2008; Nguyen et al. 2010a; Tavris et al. 2010). Furthermore, in women higher 
rates of procedural complexity, peripheral complications, and bleeding after PCI 
have been reported in contemporary large real-world studies (Tillmanns et al. 
2005; Marso et al. 2007; Alfredsson et al. 2011; Al-Fiadh et al. 2011; Pu et al. 
2011; Ortolani et al. 2012).  
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The effect of DM on the outcomes of AMI 
It is estimated that by 2030 the prevalence of DM will have risen to 7.7% 
among adult population, which is three times higher than in 2000. DM is one of 
the most frequent co-morbidity to complicate the management of patients with 
AMI. It increases the risk of mortality 2- to 5-fold compared with the non-
diabetic subjects of similar age (Koek et al. 2007; Kahn et al. 2012; Brener et 
al. 2012). AMI patients with DM also have higher rates of recurrent AMI, and a 
need for repeated coronary artery revascularization (Lee et al. 2012). The 
underlying reason for this is that diabetic patients with CAD have more often 
plaques with characteristics of plaque vulnerability, multi-vessel disease, and 
increased inflammatory status compared with non-diabetic patients (Hong et al. 
2009).  
 
The effect of DM on the sex-specific outcomes of AMI 
The prevalence of DM is higher in men than in women but there are more 
women with DM than men (Wild et al. 2004). The prevalence of DM is ex-
pected to rise more rapidly in women than in men (International Diabetes 
Federation, Diabetes Atlas 2011). This will inevitably result in increasing pro-
portions of female AMI patients with DM.  
Women and diabetics are more prone to develop diffuse small-vessel disease 
and therefore diabetic women have more frequently diabetic cardiomyopathy 
than diabetic men. DM is also associated with a significantly higher prevalence 
of left ventricular hypertrophy and left atrial enlargement in hypertensive 
women but not in men (Tenenbaum et al. 2003). There are some fundamental 
biological differences in the composition of the atherosclerotic plaque between 
men and women (Boccuzzi et al. 2005; Kamran et al. 2008; Mortensen et al. 
2009; Reynolds et al. 2011). Also the role of the lack of ovarian hormones with 
cardiovascular protective effects in postmenopausal women is widely discussed 
(Vaccarino et al. 2011). The mechanisms associated with the onset of AMI may 
be compromised to a greater extent in women than in men with DM as there are 
sex differences in endothelial dysfunction, myocardial contractile function, 
neuroendocrinal regulatory mechanisms, sensitivity to aggregating stimuli of 
platelets, and tolerance to stress (Graham et al. 2003; Ren et Ceylan-Isik 2004; 
Jacobs 2009). Women have a more pronounced inflammatory reaction to 
hyperglycemia than men, making women with DM a high risk group for 
cardiovascular adverse events (Sheikh et al. 2012; Kawamoto et al. 2011). 
Studies on the effect of DM on the sex-specific outcomes of AMI are scarce 
and demonstrate conflicting results. These have included mixed cohorts of 
patients with stable and unstable coronary artery disease where variable pro-
portions of patients undergo PCI (Rosengren et al. 2001; Crowley et al. 2003; 
Maier et al. 2006;  Champney et al. 2007; Ouhoummane et al. 2009; Meisinger 
et al. 2010; Winell et al.  2010; Ogita et al. 2011; Eliasson et al. 2011). 
Furthermore, these studies have mostly concentrated on all-cause mortality 
only. It is possible that women with DM may need more specifically targeted 
management strategies when undergoing PCI for AMI. 
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3. AIMS OF THE RESEARCH 
The overall purpose of the work was to evaluate the changes in the baseline 
characteristics, management and outcomes of patients with AMI in Estonia 
during the last decade as well as to study the long-term outcomes after PCI in 
different AMI patient subgroups. 
 
The present study consisted of the following aims: 
1. To determine the changes in in-hospital management as well as in 30-day 
and 3-year mortality of AMI patients hospitalized into tertiary vs secondary 
care hospitals in Estonia in 2001 and 2007. 
2. To compare the management, in-hospital outcomes, and 1-year mortality of 
AMI patients first admitted to tertiary and secondary care hospitals in 
Estonia in 2007.  
3. To compare the long-term outcomes of patients with STEMI and NSTEMI 
who have undergone PCI in terms of non-fatal AMI, revascularization, and 
all-cause mortality. 
4. To evaluate the sex-specific outcomes of diabetic and non-diabetic patients 
with AMI who have undergone PCI in terms of non-fatal AMI, revascula-
rization, and all-cause mortality. 
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4. METHODS 
4.1. Study design 
Paper I and Paper II 
Cross-sectional studies based on patient records.  
 
Paper III and Paper IV 
Registry linkage studies conducted by linking data from the following regist-
ries: the Estonian Myocardial Infarction Registry (EMIR), the Estonian Health 
Insurance Fund (EHIF) database, and the Estonian Population Registry (EPR). 
Data linkage was done with the help of a unique personal identification number 
assigned to all persons at birth or at immigration to Estonia. 
 
The EMIR was founded in 2001 with the purpose to perform continuous sur-
veillance of AMI management and outcomes across Estonian hospitals. Due to 
legal and economic reasons the current database includes AMI cases since 2006 
and hospitals have been reporting cases on a voluntary basis. In January 2012 
the EMIR became a national registry and reporting to the registry is mandatory. 
The EMIR has a scientific board which consists of representatives from 
Estonian hospitals.  
Data are reported to the database through an electronic web-based form 
which includes the following information: personal data (including unique 
personal identification number); cardiovascular risk factors; management, in-
vestigations, and outcomes during hospitalization; recommendations for out-
patient management. The dataset complies with the Cardiology Audit and 
Registration Data Standards in Europe (CARDS 2004).  
 
 
4.2. Study populations 
Paper I and Paper II 
The formation of the study samples is presented in Fig 3. The list of all AMI 
cases (main diagnosis code I21–I22 according to ICD-10) hospitalized from 
January 1 to December 31, 2001 and 2007, was obtained from the database of 
the EHIF. The Estonian health insurance system is a social insurance relying on 
the principle of solidarity and of the 1.3 million inhabitants about 95% are 
insured. 
The EHIF applied the following exclusion criteria for case selection: (1) 
patients who were treated as transferred cases in one of the study hospitals; (2) 
patients who were re-admitted with AMI within 28 days of the first admission; 
and (3) patients whose length of hospital stay was less than 3 days if they were 
discharged alive and were not transferred to another hospital, which made the 
diagnosis of AMI unlikely.  
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In 2001, according to the EHIF database, 2365 AMI cases were hospitalized 
during the study period. The management of AMI patients was shared among 
27 Estonian hospitals with a different number of beds. As we aimed to evaluate 
the management of AMI patients in hospitals that treat the major proportion of 
annual AMI cases, the study included 9 hospitals: 2 tertiary PCI-capable and 7 
secondary care hospitals (Table 3). After the application of the exclusion criteria 
by the EHIF, there remained 1955 cases, out of which a random sample of 520 
cases (27%) was formed. Sampling was performed by clusters according to the 
hospitals involved. 
The study cohort of Paper I in year 2007 and the study cohort of Paper II 
were the same. Altogether 3251 AMI cases were hospitalized in Estonia. Due to 
changes in the hospital network only 20 hospitals admitted AMI patients in 
2007. The study included 16 hospitals that treated the major proportion of 
annual AMI cases: 2 tertiary 24/7 PCI-capable and 14 secondary care hospitals. 
The tertiary care hospitals were the same in both time periods. After the 
application of the exclusion criteria by the EHIF, there remained 2862 cases, 
out of which a random sample of 800 cases (28%) was formed. Sampling was 
performed in clusters according to the hospitals involved.  
 
 
Table 3. Hospitals involved in Paper I and Paper II 
 
Type of hospital Paper I, year 2001   Paper I, year 2007  
Paper II 
Tertiary care 
 
North Estonia Medical Centre  
Tartu University Hospital 
North Estonia Medical Centre  
Tartu University Hospital 
Secondary care 
 
East-Tallinn Central Hospital  
East-Viru Central Hospital  
Narva Hospital  
Pärnu Hospital  
South-Estonia Hospital  
Viljandi Hospital  
West-Tallinn Central Hospital 
East-Tallinn Central Hospital  
East-Viru Central Hospital  
Narva Hospital  
Pärnu Hospital  
South-Estonia Hospital  
Viljandi Hospital  
West-Tallinn Central Hospital 
Hiiumaa Hospital  
Järvamaa Hospital  
Kuressaare Hospital  
Läänemaa Hospital  
Rakvere Hospital  
Rapla Hospital  
Valga Hospital 
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 Figure 3. Formation of the study samples for Paper I and Paper II. For Paper II only the 
cases hospitalized in 2007 were included. 
AMI, acute myocardial infarction; EHIF, Estonian Health Insurance Fund 
 
 
Paper III and Paper IV  
The studies included consecutive AMI cases hospitalized into a tertiary care 
PCI centre, Tartu University Hospital, from 1 January 2006 until 31 December 
2009. We included only cases which had undergone PCI during the index 
hospitalization. If a patient was admitted several times with AMI during the 
study period, we included only the first case of hospitalization into the study. 
According to the internal audit conducted for the purpose of this study, the case 
coverage for the study period was 99.8%. EMIR provided the following data: 
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(1) patient baseline characteristics (including the diagnosis of DM and the 
subtype of AMI); (2) prescription of medications during hospitalization and for 
outpatient use; (3) use of coronary angiography, revascularization, and echo-
cardiography during the index hospitalization; and (4) in-hospital outcomes.  
Data on mortality during the follow-up was obtained from the EPR.  
Data on the non-fatal AMI and repeated revascularization during follow-up 
was provided by the EHIF. Consistency in reporting to the EHIF database and 
the validity of the data has been established (Ministry of Social Affairs of 
Estonia and WHO Regional Office for Europe 2004). Data on non-fatal AMI 
included the date of hospitalization and the diagnosis code according to the 
ICD-10 classification (I21–I22, main diagnosis). The EHIF provided the data on 
the method and date of revascularization according to the Nordic Medico-Sta-
tistical Committee Classification of Surgical Procedures, version 1.6: percuta-
neous coronary intervention (procedure code FNG with numeric characters of 
the code) and coronary artery bypass graft (procedure codes FNA, FNC, and 
FNE with numeric characters of the codes) (Nordic Medico-Statistical Com-
mittee 2001). 
 
 
4.3. Data collection 
Paper I and Paper II 
Data from medical records were retrospectively abstracted by the study experts 
according to a standardized data collection form. Most of the experts were 
certified cardiologists and all had received additional training in data collection 
for this study. Data quality was monitored by random re-abstractions for deter-
mining the causes of discrepancies and followed by retraining of the experts. 
The abstracted data included: (1) patient baseline characteristics; (2) coronary 
angiography, revascularization, and non-invasive cardiac testing during hospi-
talization; (3) in-hospital and discharge medications; and (4) in-hospital morta-
lity. The date of death during 3-year follow-up was obtained from the Estonian 
Population Register by the EHIF.  
In Paper I we aimed to assess the quality of care of the first hospital where a 
patient was hospitalized, so data collection stopped when patients were trans-
ferred from a secondary care to a tertiary care hospital.  
In Paper II all procedures performed on a patient, as well as in-hospital and 
discharge medications, in-hospital outcomes, and 1-year mortality were attri-
buted to the hospital where the patient was admitted first, even if he/she from a 
secondary care hospital had been referred to a tertiary care hospital.  
 
Paper III and Paper IV 
Data collection into the EMIR in Tartu University Hospital is organized at the 
hospital level. The data is collected in a prospective manner by trained 
personnel. Data on follow-up was obtained from the databases of the EHIF and 
EPR. 
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4.4. Definitions 
Definition of AMI 
In all four studies, the diagnosis of AMI was based on the redefinition 
document of AMI published in 2000 (Alpert et al. 2000). Troponin T was used 
as the primary biochemical marker, and the cut-off value for the diagnosis of 
AMI was set at ≥0.10 ng/ml. Additionally, patients who died before cardiac 
markers were obtained, or patients whose cardiac markers did not exceed the 
cut-off value because of a too short time interval from attack onset, the presence 
of a new ST-segment elevation with symptoms suggestive of myocardial 
ischemia was considered to meet the AMI criteria.  
AMI was classified as STEMI if there was a new or presumed new ST 
segment elevation at the J point in two or more contiguous leads with the cut-
off points ≥0.2 mV in leads V1, V2, or V3 and ≥0.1 mV in other leads; or if 
there was evidence of a new or presumed new left bundle branch block. 
 
Definition of DM 
Patients are classified as diabetic if they have a history of DM documented by a 
physician, or patients are diagnosed with DM during the current episode.  
 
 
4.5. Study outcomes 
Paper I 
30-day and 3-year all-cause mortality 
 
Paper II 
Outcomes during hospitalization (ventricular fibrillation/cardiac arrest, cardio-
genic shock, cardiogenic pulmonary edema, re-infarction, stroke, bleeding comp-
lications, mechanic complications, and mortality) and 1-year all-cause mortality 
 
Paper III and Paper IV  
The primary composite outcome was defined as the following: non-fatal AMI, 
repeated revascularization (coronary artery bypass-grafting; target or new lesion 
PCI), or all-cause mortality whichever occurred first. Follow-up started on the 
date of PCI during index hospitalization and ended if a case reached the primary 
outcome, or the follow-up period ended (31 December 2010). We also studied all-
cause mortality separately as a secondary outcome. For all-cause mortality, 
follow-up ended when the patient died or reached the date for the end of follow-
up. 
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4.6. Statistical analysis 
In all four studies categorical variables were expressed as frequencies and per-
centages, and continuous variables as means and standard deviations (SD), or as 
medians and interquartile ranges (IQR). To compare study the groups in respect 
to baseline characteristics, in-hospital management and discharge prescription 
rates of medications, the Chi-Square or the Fisher’s exact test for categorical 
variables and the t-test for two independent samples or the Wilcoxon-Mann-
Whitney test for continuous variables were used.  
Two-sided p values ≤0.05 were considered statistically significant. Analyses 
were performed using the statistical softwares of Stata, version 11 (StataCorp 
2009) and the R, version 2.10.1 (Crawley 2010). 
 
The outcome analysis in separate studies 
Paper I 
The outcome was expressed as 30-day and 3-year mortality. The crude and 
baseline-adjusted (age, sex, AMI subtype, DM, arterial hypertension, previous 
AMI, chronic heart failure) hazard ratios (HRs) of mortality for patients 
admitted into the tertiary and secondary care hospitals in 2001 vs 2007 were 
estimated with Cox’s proportional hazards regression. The ratio with the 95% 
confidence interval (CI) was presented as the ratio of the rate in 2007 to the rate 
in 2001 in the tertiary or secondary care hospitals.  
The experts found that the documentation of smoking status and lipid pro-
files in medical records was incomplete in 2001 and 2007 (percentage of 
missing values ranged from 14.5–48.8) and those variables were not further 
analyzed in the patient characteristics of the results section.  
 
Paper II 
The crude odds ratios (ORs) for differences in in-hospital outcomes for patients 
first admitted to tertiary vs secondary care hospitals was estimated using logistic 
regression. The crude HR for 1-year mortality was estimated with Cox’s pro-
portional hazards regression. The ratio with the 95% CI was displayed as the 
ratio of the rate in tertiary care hospitals to the rate in secondary care hospitals.  
Owing to the study design, the dataset included missing values for variables 
concerning cardiovascular history and risk factors. Values were missing at 
random. The percentage of missing values ranged from 3.5 to 28.7. In our 
analysis, we excluded variables with missing values for more than 15% of the 
cases. Hence data on smoking and Body Mass Index were not included in the 
analysis. When comparing the differences in in-hospital outcomes and 1-year 
mortality between the two study groups, we adjusted for baseline characteristics 
(age, sex, AMI subtype, DM, arterial  hypertension, dyslipidemia, previous 
AMI, chronic heart failure, previous stroke, peripheral vascular disease, pre-
vious PCI, previous CABG, out-of-hospital cardiac arrest, Killip class III/IV on 
admission). We used case deletion and multiple imputation as comparative 
approaches to handling patients with missing observations. Performing full-case 
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analysis would have led to biased analysis and would have excluded 22.9% of 
the cases. We performed multiple imputation for all baseline characteristics 
with missing values (van Buuren et al. 1999): DM, arterial hypertension, dys-
lipidemia, previous AMI, previous chronic heart failure, previous stroke, 
previous peripheral vascular disease, and previous PCI. We used 10 imputed 
datasets for this study to ensure that our effect estimates were not overly 
inaccurate due to Monte Carlo variability.  
 
Paper III  
Cox’s proportional hazards regression was used to calculate HRs of primary and 
secondary outcome with the 95% CIs to compare the outcomes of STEMI 
patients to NSTEMI patients. The multivariate model included baseline charac-
teristics (age, DM, arterial hypertension, dyslipidemia, current smoking, pre-
vious AMI, chronic heart failure, previous stroke, peripheral vascular disease, 
previous PCI, previous CABG, Killip class III/IV on admission, LVEF <40%) 
and the number of diseased vessels (1–2 or 3–4 vessel disease). 
 
Paper IV 
Cox’s proportional hazards regression was used to calculate HRs of primary and 
secondary outcome with the 95% CIs to compare the outcomes of diabetic and 
non-diabetic patients by sex. The multivariate model included baseline charac-
teristics (age, AMI subtype, arterial hypertension, dyslipidemia, current 
smoking, previous AMI, chronic heart failure, previous stroke, peripheral 
vascular disease, previous PCI, previous CABG, Killip class III/IV on 
admission, LVEF <40%,  the number of diseased vessels (1–2 or 3–4 vessel 
disease), and the delay to first medical contact. 
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5. RESULTS 
Baseline characteristics 
Compared to 2001 in 2007 the patients hospitalized for AMI had become 
older – approximately 40% of patients were over 75 years old. The increase in 
the mean age was especially pronounced in the secondary care hospitals: when 
in 2001 the mean age of AMI patients in both types of hospitals was about 68 
years, then in 2007, the patients in the secondary care hospitals were about two 
years older than the patients in the tertiary care hospitals (Table 1, Paper I; 
Table 1, Paper II).  
An important finding was that the rate of patients with DM had doubled by 
2007 in both types of hospitals (Table 1, Paper I). In the secondary care hos-
pitals a higher proportion of patients were hypertensive in 2007 than in 2001. 
Furthermore, in 2007 the rate of hypertensive patients was higher in the 
secondary care hospitals than in the tertiary care hospitals (Table 1, Paper II). 
The further comparison between the two hospital types in 2007 revealed that 
the patients admitted to the tertiary care hospitals were more likely to have a 
history of prior PCI and out-of-hospital cardiac arrest. In contrast, the patients 
first admitted to the secondary care hospitals were more likely to present later at 
the hospital after symptom onset (Table 1, Paper II). 
 
Recommendation of medications  
The use of evidence-based medications was higher in 2007 compared to 2001 in 
both types of hospitals. In the tertiary care hospitals the rates for ASA reached 
94%, however the rates for beta-blockers, ACEIs and/or ARBs, and statins 
remained below 83%. In 2007 in the secondary care hospitals the respective 
rates were even lower, especially for statins that were recommended for less 
than 38% of patients (Table 2 and 3, Paper I). When making comparisons 
between the two hospital types we observed that the recommendation of nitrates 
for out-patient use was considerably higher in the secondary care hospitals, 
respectively 46% vs 22% (Table 3, Paper II).   
 
Reperfusion for STEMI  
The patients of the tertiary care hospitals underwent reperfusion for STEMI 
almost twice as often in 2007 as in 2001 (42% vs 64%) and primary PCI be-
came the reperfusion method of choice. Still, the door-to-needle and door-to-
balloon delay times were long. 
Meanwhile, the reperfusion rates did not change significantly in the 
secondary care hospitals (Table 2, Paper I). In fact, the STEMI patients first 
5.1. Changes in the baseline characteristics, management 
and outcomes of AMI in the tertiary and secondary care 
hospitals in Estonia (Paper I and Paper II) 
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admitted to secondary care hospitals were almost twice as unlikely to receive 
reperfusion as those first admitted to tertiary care hospitals (38% vs 64%; Table 
2, Paper II).  
In 2007 a major reason for not receiving reperfusion for patients from both 
types of hospitals was a long prehospital delaly (Paper II). Nevertheless for 13% 
in the tertiary care hospitals and for 29% in the secondary care hospitals the 
reason for not performing reperfusion was not clear. 
 
Coronary angiography and revascularization 
The patients of the tertiary care hospitals underwent coronary angiography and 
revascularisation up to two times more often in 2007 as in 2001 and about 80% 
were referred for coronary angiography (Table 2, Paper I).  
In the secondary care hospitals a higher rate of patients was referred into a 
tertiary care hospital for further management in 2007 than in 2001 (21% vs 7%, 
respectively). Those selected for coronary angiography were more likely to be 
younger, have STEMI and a history of prior PCI. In contrast, the non-selected 
patients had higher rates of prior AMI, chronic heart failure, prior stroke and 
Killip class III/IV at presentation. Nevertheless, in 2007 the rates of coronary 
angiography were three times higher for patients first admitted to the tertiary 
care hospitals compared to those admitted to the secondary care hospitals, 80% 
vs 25% respectively (Table 2, Paper II).  
 
Non-invasive risk stratification 
In 2007, echocardiography was performed more frequently in patients first 
admitted to tertiary care hospitals than in those admitted to secondary care 
hospitals, respectively 85% vs 65% (Paper II).  
 
Outcomes 
In crude and baseline-adjusted analysis there were no significant differences in 
the 30-day mortality and 3-year mortality within the two hospital types in 2007 
compared to 2001 (Table 4, Figure 4). 
However, in 2007, the short-term mortality was significantly lower in the 
tertiary care hospitals than in the secondary care hospitals in crude and baseline-
adjusted analysis (Table 4, Paper II). The differences in the mortality persisted 
also after one year (Table 4 and Figure 1, Paper II) and three years (Paper I) of 
follow-up. 
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Table 4. Mortality of patients hospitalized into tertiary and secondary hospitals in 
Estonia in 2001 and 2007 
 
 Year 
2001 
Year 
2007 
  
Mortality % % p Adjusted HR (95% CI) 
30-day     
Tertiary care hospitals  17.6 13.2 0.156 0.69 (0.42–1.13) 
Secondary care hospitals 20.2 22.5 0.516 1.01 (0.66–1.55) 
3-year     
Tertiary care hospitals 35.7 32.7 0.475 0.90 (0.65–1.23) 
Secondary care hospitals 38.5 45.3 0.113 1.03 (0.77–1.37) 
CI – confidence interval; HR – hazard ratio 
 
 
 
Figure 4. Baseline-adjusted 3-year cumulative mortality hazards of patients hospita-
lized into tertiary and secondary care hospitals in Estonia in 2001 and 2007  
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5.2. Long-term outcomes  
in different AMI patient subgroups after PCI   
Long-term outcomes according to the AMI subtype (Paper III) 
From the 2330 AMI cases hospitalized during the study period, 83% of STEMI 
and 55% of NSTEMI patients underwent PCI (p<0.001) and were included into 
the final study sample.  
Compared to those not selected for PCI the STEMI and NSTEMI patients 
from the PCI group were about five years younger and they had less frequently 
chronic heart failure, previous stroke, peripheral artery disease and acute heart 
failure at presentation.  
STEMI patients, compared to those with NSTEMI, were more often current 
smokers and they had acute heart failure on presentation (Table 1, Paper III). 
Meanwhile the NSTEMI patients had more often hypertension, previous AMI, 
chronic heart failure and they had undergone revascularization previously. 
There were no major differences in the extent of coronary artery disease 
between the two study groups (Table 2, Paper III). There were also no major 
differences in the use of guidelines-recommended  medications, except for 
heparins and glycoprotein IIb/IIIa receptor inhibitors during hospitalization that 
were more often used in STEMI patients (Table 3, Paper III).  
Among the patients with STEMI 72% received reperfusion within 12 h after 
symptom onset. The method of reperfusion was primary PCI in 86% of patients 
and thrombolysis in 14% of patients, which was done for patients referred from 
secondary care hospitals. Among the patients with NSTEMI 16% and 69% of 
patients received PCI respectively within 2 hours and 12 hours for after arrival 
to the hospital.  
In crude analysis, patients with STEMI had higher rates of primary and 
secondary outcome than patients with NSTEMI (Table 5). The patients with 
STEMI had worse long-term outcomes also after adjustment for baseline 
characteristics: HR for primary outcome 1.30 (95% CI 1.09–1.56) and for 
secondary outcome 1.57 (95% CI 1.19–2.08).  
 
 
Table 5. Outcomes during follow-up among patients with STEMI and NSTEMI who have 
undergone percutaneous coronary intervention, Tartu University Hospital, 2006–2009 
Outcomes STEMI (n=1107) NSTEMI 
(n=545) 
p 
 % %  
Primary outcome 41.8 34.8 0.007 
Non-fatal AMI 9.6 9.7  
Revascularization 12.0 12.5  
Death 20.2 12.7  
Secondary outcome 22.0 15.4 0.001 
In-hospital death 6.9 3.8 0.014 
AMI – acute myocardial infarction; NSTEMI – non-ST-segment elevation myocardial 
infarction; STEMI – ST-segment elevation myocardial infarction 
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Sex-specific long-term outcomes of diabetic patients (Paper IV) 
Of the 2330 patients with AMI hospitalized during the study period, 75% men 
and 65% women underwent PCI during the index episode (p<0.001) and were 
included into the study. In the final study population 15% of men and 24% of 
women had DM (p<0.001). 
Overall, the patients with DM had higher rates of cardiovascular risk factors, 
co-morbidities, and 3–4 vessel disease among both men and women. Women 
with DM were younger, had longer delay times to first medical contact, and 
presented less frequently with typical symptoms of chest pain than those 
without DM (Table 1, Paper IV). 
During the index hospitalization among women with STEMI a significantly 
lower proportion of patients with DM than those without received reperfusion 
within 12 hours after symptom onset (Table 2, Paper IV). When assessing the 
utilization of medications during the index hospitalization, women with DM 
were found to receive ASA less often than those without DM (Table 3, Paper 
IV). Men with DM received more often management with ACEIs and/or ARBs 
than men without DM. The rates of recommendation of the studied drugs for 
out-patient management were similar to the rates of drug utilization during the 
index hospitalization, though no differences within sex-groups were observed.   
In univariate analysis, patients with DM both among men and women had a 
higher risk of primary and secondary outcome (Table 6). In multivariate 
analysis, however, DM was associated with a higher risk of primary and 
secondary outcome only in women (Table 6; Fig 1 and 2, Paper IV).  
 
 
Table 6. Crude and adjusted hazard ratios for outcomes during follow-up after percuta-
neous coronary intervention among men and women with diabetes compared to those 
without diabetes, Tartu University Hospital, 2006–2009 
 Men Women 
Outcome HR (95% CI) AHR (95% CI) HR (95% CI) AHR (95% CI) 
Primary¥ 1.54 (1.20–1.98)* 1.29 (0.98–1.68) 1.60 (1.21–2.13)* 1.44 (1.05–1.96)* 
Secondary€ 1.53 (1.06–2.20)* 1.19 (0.80–1.76) 1.65 (1.11–2.44)* 1.83 (1.17–2.89)* 
AHR – adjusted hazard ratio  
HR – hazard ratio 
¥Primary outcome – non-fatal AMI, revascularization, or all-cause mortality 
€Secondary outcome – all-cause mortality 
*p < 0.05 
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6. GENERAL DISCUSSION 
6.1. Changes in the baseline characteristics, management 
and outcomes of AMI in the tertiary and  
secondary care hospitals in Estonia  
6.1.1. Changes in the baseline characteristics  
The higher age of the AMI patients in 2007 compared to 2001 is probably 
caused by the fact that the uptake of effective primary prevention methods has 
shifted the age for the onset of AMI. In any case, higher age increases the risk 
for worse outcomes and poses a challenge for the treatment of AMI patients. 
An important finding that has also been noted previously (Fang et al. 2010) 
was that the proportion of patients with DM had doubled by 2007. This 
probably mirrors the rising prevalence of glycometabolic disturbances in the 
population (Wild et al. 2004; International Diabetes Federation, Diabetes Atlas 
2011). The reason for the higher rate of patients with hypertension in the 
secondary care hospitals could first be that in 2007 the patients were older and, 
secondly, that the clinicians increasingly recognize hypertension as an im-
portant cardiovascular risk factor. 
Our study did not include information about non-cardiovascular co-morbi-
dities such as chronic kidney disease and cancer which could be more prevalent 
among older patients and could influence management decisions and prognosis. 
Still, overall it seems that the trends in the patterns of differences in the baseline 
characteristics of AMI patients in different types of hospitals were similar to 
those reported in previous studies (Labarere et al. 2007; Radovanovic et al. 
2010): patients admitted into secondary care hospitals were older, more 
frequently female, hypertensive, and had more severe co-morbidities. There 
could be two explanations for this: first, emergency medical services tend to 
transport younger (who are more often male) and healthier AMI patients into 
tertiary care facilities, and second, patients living in the rural area tend to be 
older, have  more co-morbidities and be more often of female sex.  
6.1.2. Changes in the management  
Our country-wide study showed that in Estonia the management of patients with 
AMI improved both in the tertiary and secondary care hospitals between 2001 
and 2007; however, the progress was not uniform. 
Evidently the observed improvements of management were partly due to the 
release of the new European and Estonian guidelines for the management of 
AMI (Bertrand et al. 2002;  Braunwald et al. 2002; Van de Werf et al. 2003; 
Antman et al. 2004; Soopõld et al. 2004) as well as the launching of several 
training programs at the ESC and hospital level. Thus much effort has been put 
into improving the implementation of the recommendations of the diagnosis and 
management guidelines for AMI. The process of improvement in management 
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quality has also involved the awareness of the importance of risk factor 
modification among AMI patients. The progress done is mirrored by the decline 
in the rate of missing data in the patient files for such cardiovascular risk factors 
as dyslipidemia, smoking and BMI.  
 
Changes in the recommendation of medications  
An encouraging finding was the increased use of ASA in 2007 compared to 
2001 in the tertiary care hospitals. However, in the secondary care hospitals 
only about 85% of the patients were recommended ASA during hospitalization 
and for out-patient use. As ASA is a well established drug in the secondary 
prevention of AMI (Antithrombotic Trialists' Collaboration 2009), we believe 
that the low rates of recommendation are at least to some extent related to the 
deficiencies in the documentation in the patient files. 
The recommendation of beta-blockers and ACEIs/ARBs increased in both 
types of hospitals. Still, in 2007, the mean rate of recommendation of these 
drugs during hospitalization and for outpatient use remained below 83%. In 
fact, similar rates were also found in the GRACE (Goodman et al. 2009) and in 
the second Euro Heart Survey on acute coronary syndromes (Mandelzweig et 
al. 2006). An interesting finding was that in the secondary care hospitals the 
rate of recommendation of such older drugs as beta-blockers was quite similar 
to the rate in the tertiary care hospitals. At the same time, although the 
recommendation of ACEIs/ARBs had increased considerably during the study 
period in the secondary care hospitals, the rates remained still lower than in the 
tertiary care hospitals. The use of statins in the secondary care hospitals causes 
concern as although the rates increased markedly during the study period, their 
use was still below 38%. The fact that the quality of care of AMI patients in the 
secondary care hospitals lags behind that in their tertiary care counterparts may 
be due to the known slower implementation of guideline-recommended medi-
cations in the secondary care hospitals in general (Dorsch et al. 2004). As our 
study demonstrated, patients in the secondary care hospitals tend to be older and 
have more co-morbidities, which may influence management decisions. 
The results of our study demonstrated that although the recommendation of 
medications improved in both types of hospitals between 2001 and 2007 the 
developments are still suboptimal. We suspect that one of the major reasons for 
this is the “risk-management paradox” wherein higher-risk patients are less 
likely to receive guideline recommended therapies (Sabouret et al. 2010; 
Abtahian et al. 2011; Motivala et al. 2011). This phenomenon is probably more 
pronounced in secondary care hospitals, where the patients are older and have 
more co-morbidities and possibly also poorer functional capacity. Clinicians 
perhaps preferentially avoid preventive therapies out of the fear of non-
compliance to prescribed medications. It should be admitted that this pre-
judgment by clinicians is justifiable. However, a recent study found that even in 
the absence of co-morbidity, elderly patients were denied indicated medical 
managements probably because of their age alone (Moubarak et al. 2012). 
Another reason for this “risk-management paradox” is probably the fact that 
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clinicians are concerned about applying evidence from clinical trials to their 
everyday practice because trials tend to exclude older higher-risk patients.  
The existence of the “risk-management paradox” must be kept in mind when 
clinicians feel reluctance to initiate or continue therapies to patients presenting 
with an AMI. Whenever possible, objective data should be used to carefully 
weigh the risks and the benefits before withholding evidence-based therapies in 
these patients as there may be misperceptions regarding contraindications and 
lack of tolerability to medications in older patients. Management approaches 
that have proven to be associated with lower risk of complications should be 
preferred. For instance, temporal changes in the antithrombotic strategies have 
led to a nearly 20% reduced risk of post-PCI bleeding (Subherwal et al. 2012). 
Additionally, patients in secondary care hospitals may benefit from the routine 
onsite rotations of cardiologists from tertiary care hospitals (Joynt et al. 2011; 
Bradley et al. 2005; Bradley et al. 2012). 
 
Changes in the reperfusion therapy for STEMI 
While between 2001 and 2007 in the tertiary care hospitals reperfusion rates 
increased and primary PCI became the preferred method of reperfusion for 
STEMI, then in the secondary care hospitals the reperfusion rates showed little 
change.  
Nevertheless, only 64% of the patients in 2007 in the tertiary care hospitals, 
received reperfusion (primary PCI 57%), 33% within the recommended time 
windows after hospital admission. Although further studies are needed, the 
reperfusion rates and the in-hospital delays remained slightly lower than the 
70%, recommended by the Stent for Life initiative (stentforlife.com), as well as 
lower than the rates reported in the third Euro Heart Survey (Schiele et al. 
2010), in the NRMI (Gibson et al. 2008), and in the GRACE (Eagle et al. 
2008). A major reason for not receiving reperfusion was a long pre-hospital 
delay. In fact, the EMIR report for 2010 for tertiary care hospitals (available at 
www.infarkt.ee) demonstrated that among the STEMI patients who presented 
within 12 hours of symptom onset and who were not transferred from a 
secondary care hospital, the rate of reperfusion was as high as 83% (75% for 
primary PCI).  
In 2007, STEMI patients admitted to secondary care hospitals were twice as 
unlikely to receive reperfusion compared to patients first admitted to tertiary 
care hospitals. The reasons for such a difference are not clear. It is possible that 
some STEMI patients were transferred into a tertiary care hospital for primary 
PCI before they received thrombolysis at the secondary care hospital. Still, in 
29% of the cases the reason for not performing reperfusion was not clear for the 
study experts. There might be deficient documentation of contraindications for 
thrombolysis in patient files, such as the risk of bleeding and a recent stroke. 
Additionally, clinicians probably tend to be quite conservative in treating 
elderly persons with thrombolysis as they have a higher risk of stroke (the 
GUSTO investigators 1993). The reasons for the low rates of reperfusion in the 
secondary care hospitals are probably a combination of high age of the patients 
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and late presentation at hospital, little experience of clinicians in performing 
thrombolysis, and insufficient implementation of the recommendations in the 
guidelines.  
A possible solution that might help increase the proportion of STEMI 
patients who receive reperfusion within 12 hours of symptom onset is the 
electronic transmission of ECG from ambulance to hospital (Sorensen et al. 
2011). In the ideal case, the contraindications for thrombolysis should be 
assessed already in the ambulance so that patients could be transported 
appropriately. In selected cases the patients could benefit more from primary 
PCI than from thrombolysis, even at the expense of a longer delay (Tarantini et 
al. 2010; The GUSTO investigators 1993; De Luca et al. 2008).  
 
Changes in the use of coronary angiography and revascularization  
In 2007, patients with AMI in the tertiary care hospitals underwent two times as 
frequently coronary angiography and revascularization than in 2001. At the 
same time, in the secondary care hospitals, the transfer of patients for further 
cardiac testing and revascularisation into tertiary care hospitals increased. Still, 
the transfer rates remained low compared to previous studies (Radovanovic et 
al. 2010;  Labarere et al. 2007).  
Our study suggests uneven access to PCI facilities across Estonian hospitals. 
In 2007, the patients primarily admitted to secondary care hospitals were three 
times less likely to undergo coronary angiography compared to the patients 
primarily admitted to tertiary care hospitals. Similarly to the study of Muus et 
al. (2011), an important finding of this study was that in the secondary care 
hospitals the patients selected for transfer into a higher care facility for further 
management, including PCI, were younger and healthier; they had more 
frequently STEMI and a better clinical status on presentation compared to those 
who were not selected for PCI. As previous studies (Stukel et al. 2005; Cohen 
et al. 2009) have shown in both hospital types the use of coronary angiography 
appears to target younger, lower risk patients who would derive less benefit 
from revascularization. Yet in secondary care hospitals, age seems to be a much 
stronger selection determinant and referral for coronary angiography and 
consequent revascularization is even more biased than in tertiary care hospitals.  
The results of our paper III characterize trends in the selection of patients for 
PCI in a tertiary care hospital in more detail. Much higher rates of patients with 
STEMI than with NSTEMI are selected for PCI (83% vs 55%). This is wholly 
understandable as according to the guidelines, in the absence of contra-
indications all STEMI patients should receive reperfusion, and in tertiary care 
hospitals the preferred method is primary PCI. Regarding patients with 
NSTEMI, indications for coronary angiography and PCI and the timing of it 
depend more on the symptoms, clinical presentation, and risk stratification. Like 
in previous studies (Sabouret et al. 2010;  Motivala et al. 2011), NSTEMI 
patients who underwent PCI were younger and had lower rates of cardiac co-
morbidities than those who were not selected for this procedure.  
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It can be speculated that certain invasive in-hospital therapies were withheld 
from higher-risk patients out of a genuine concern for the risk of adverse effects 
in these patients. The patients themselves may also have been less ready to take 
the risk associated with an invasive procedure. Still, the “risk-management 
paradox” must be kept in mind and objective data should be used to make risk 
adjusted decisions for invasive management. Additionally, the use of transradial 
access is one possibility to improve outcomes as it is associated with a signifi-
cant reduction in mortality, major adverse cardiovascular events, and major 
access site complications compared with a transfemoral approach (Mamas et al. 
2012).  
It is evident that universal triage/transfer of all AMI patients to tertiary care 
hospitals would on exceed their capability (Wharton et al. 2001; Bosk et al. 
2011). The key factor in this case is to promote partnerships between hospitals 
with and without the availability of PCI.  
 
Changes in the non-invasive risk stratification  
It could be expected that in hospitals where PCI is not available, non-invasive 
risk stratification (incl. stress-testing) is more often used to select patients for 
referral to coronary angiography and revascularisation into a higher care 
hospital. Like a study of Halabi et al. (2006), our study found a low use of 
stress-testing in secondary care hospitals. Furthermore, the use of echocardio-
graphy was significantly lower than in tertiary care hospitals. To some extent, 
this could be explained by the lower on-site availability of these investigation 
methods. However, when considering the low rates of patients selected for 
referral, it can be hypothesized that the cardiovascular risk stratification of AMI 
patients in secondary care hospitals is suboptimal, which could also explain the 
higher need to prescribe nitrates during hospitalization and at discharge. 
 
6.1.3. Changes in the short- and long-term mortality of AMI                                               
in the tertiary and secondary care hospitals 
Several studies have demonstrated that closer adherence to published guidelines 
for AMI management have resulted in improved short- and long-term outcomes 
and this even despite the growing prevalence of risk factors (older age, history 
of dyslipidemia and DM) at presentation (Mandelzweig et al. 2006; Fox et al. 
2007; Gibson et al. 2008; Peterson et al. 2008; Rogers et al. 2008; Janion et al. 
2009; Stolt Steiger et al. 2009;  Tatu-Chitoiu et al. 2009;  Krumholz et al. 2009; 
Monhart et al. 2010;  Fang et al. 2010). Although our study demonstrated a 
marked improvement in the management of AMI patients in 2007 compared to 
2001, especially in the tertiary care hospitals, it failed to establish a significant 
decrease in short- and long-term mortality.  
It is possible that our study was underpowered to detect a mortality diffe-
rence within a hospital type. Nevertheless, these findings may largely be due to 
the higher age and higher prevalence of co-morbidities among the study 
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samples in 2007. For instance, the rates of DM had almost doubled in both 
types of hospitals. To further clarify this issue, we performed a sub-analysis 
comparing the baseline characteristics, management, and mortality separately 
among patients aged <75 and ≥75 years in 2001 and 2007 in the tertiary care 
hospitals. It suggested that in the tertiary care hospitals the reasons why better 
management had not resulted in better outcomes was that, firstly, the rate of 
patients over 75 years of age with more co-morbidities had increased and, 
secondly, improvement targeted those who were younger and healthier with a 
lower risk of mortality. This finding is supported by a previous age-group 
stratified study conducted in an Estonian tertiary care hospital during 2001–
2003. It demonstrated that patients aged <75 years had shorter pre-hospital 
delay times; they also received more often reperfusion, coronary angiography 
and PCI as well as beta-blockers and statins than those aged ≥75 years (Ainla et 
al. 2005a).  
 
6.1.4. Differences in the short- and long-term outcomes of AMI                                       
between the tertiary and secondary care hospitals in 2007 
The observed finding of lower short and long-term mortality in the tertiary care 
hospitals compared to the secondary care hospitals in 2007 is intriguing. It can 
probably be explained by a combined effect of improved management possibili-
ties in the tertiary care hospitals and different patient baseline characteristics in 
the two hospital types. The patients admitted to the secondary care hospitals 
were more likely to be older and have a higher cardiovascular risk. Moreover, 
as the elderly often present with atypical symptoms and have a greater burden 
of cardiac and non-cardiac co-morbidities, clinicians could be more reluctant to 
treat them aggressively, the more so when the outcomes of interventions and 
surgery may be poorer (Bridges et al. 2003; Alexander et al. 2005). 
These findings are consistent with the results of recent retrospective and 
prospective observational studies (Khadour et al. 2003; Tang et al. 2006; 
Labarere et al. 2007;  Radovanovic et al. 2010; Belle et al. 2012) showing that 
hospitalization to a tertiary care hospital is associated with lower in-hospital and 
long-term mortality. At the same time, with follow-up extending to three years, 
some studies have revealed no favorable impact of management in hospitals 
equipped with coronary angiography facilities on patient mortality. This 
controversy may be explained by the comparable rates of reperfusion, coronary 
angiography and revascularization, as well as by the recommendation of 
evidence-based drugs in both hospital types (Krumholz et al. 1998; Rogers et al. 
2000;  Ambardekar et al. 2010). Nor did the GRACE (Van de Werf et al. 2005) 
show survival benefit by 6 months for patients admitted to hospitals with 
coronary angiography facilities. However, many of the patients from this 
retrospective analysis were enrolled before the routine use of clopidogrel, 
glycoprotein IIb/IIIa inhibitors and drug-eluting stents, which have contributed 
to the improved outcomes observed with an invasive strategy.  
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Although our study demonstrated an outcome difference between the 
patients first hospitalized into tertiary and secondary care hospitals, it is clear 
that whether a hospital type improves outcomes depends on the magnitude of 
existing differences, not on the type of hospital alone (Chen et al. 2010).  
 
 
6.2. Long-term outcomes in different AMI  
patient subgroups after PCI                                   
Our register linkage studies among patients in a tertiary care hospital were the 
first in Estonia to assess the long-term outcomes of AMI patients who have 
undergone PCI and this not only in terms of all-cause mortality but also in terms 
of non-fatal AMI and revascularization.  
It should be recognized that AMI patients who have undergone PCI have a 
serious prognosis in terms of non-fatal AMI, revascularization and all-cause 
mortality. With a median follow-up time of almost three years, about 40% of 
the study population experienced a primary outcome event and by the end of 
follow-up 20% of the patients were dead. These findings are in accordance with 
previous studies (Abbott et al. 2007; Chan et al. 2009; McManus et al. 2011), 
although our study had a longer follow-up period. This demonstrates the fact 
that patients with AMI have a high cardiovascular risk also after hospitalization 
and proper use of guideline-recommended secondary prevention methods of 
AMI is warranted. 
 
Long-term outcomes according to the AMI subtype 
Our Paper III showed that among patients who have undergone PCI, those with 
STEMI have significantly worse long-term outcomes than those with NSTEMI. 
Furthermore, the differences are mostly driven by a higher mortality of STEMI 
patients during follow-up.  
Indeed, patients with STEMI are known to have a higher short-term risk 
(Terkelsen et al. 2005; Roe et al. 2005; Chan et al. 2009). However, as our 
findings regarding the long-term outcomes for the two AMI subtypes were 
contradictory to those obtained in previous studies including unselected cohorts, 
we concluded that NSTEMI patients selected for PCI had a lower cardio-
vascular risk than NSTEMI patients generally have. In a recent study also 
Abbot et al. (2007) found that patients with STEMI showed a trend towards 
worse outcomes during 1-year follow-up. Unfortunately, the study was under-
powered to detect a statistically significant difference.  
 
Sex-specific long-term outcomes of diabetic patients  
We found that among patients with AMI who have undergone PCI, DM is 
associated with significantly worse outcomes in women than in men. This excess 
risk seemed to be largely driven by a high in-hospital mortality of diabetic 
women. The results extend the findings of previous studies by demonstrating the 
sex-specific outcomes of diabetic patients in a cohort of AMI patients where all 
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patients have undergone PCI (Rosengren et al. 2001; Crowley et al. 2003; Maier 
et al. 2006;  Champney et al. 2007;  Ouhoummane et al. 2009;  Meisinger et al. 
2010; Winell et al.  2010; Eliasson et al. 2011; Ogita et al. 2011).  
The prerequisite for similar outcomes in diabetic and non-diabetic women is 
similar management of AMI (Kramer et al. 2012). Firstly, in our study ASA 
was recommended less frequently for women with DM than for those without 
DM. The analysis also showed that in women with STEMI, those with DM 
received less often reperfusion within 12 hours of symptom onset compared to 
those without DM. Secondly, female diabetic patients presented later and less 
often with typical symptoms of chest pain compared to non-diabetics. Medical 
professionals as well as patients with CAD should be more aware of the higher 
prevalence of atypical symptoms among women and strive towards shorter pre-
hospital delay times.  
Although in our study women with DM were younger, the rates of previous 
AMI and chronic heart failure were higher than in those without DM. Besides, 
older women with DM could have more pronounced risk factor clustering and 
worse self-rated health than older men (Leosdottir et al. 2011). This adds to the 
excess cardiovascular risk of women with DM, which in combination with 
higher age, contributes to sex-specific outcomes of AMI patients with DM 
(Norhammar et al. 2008). Therefore, in order to alleviate this unfavorable 
situation for women, improvements should target already the primary pre-
vention strategies of AMI (Kautzky-Willer et al. 2010; Franzini et al. 2012).  
As presented above, several studies have suggested possible patho-
physiological reasons for such sex-specific outcomes (Tenenbaum et al. 2003; 
Graham et al. 2003;  Ren et Ceylan-Isik 2004; Boccuzzi et al. 2005; Kamran et 
al. 2008; Mortensen et al. 2009; Jacobs 2009; Reynolds et al. 2011, Vaccarino 
et al. 2011; Sheikh et al. 2012). However, it is not clear which management 
strategies should be applied in order to improve the outcomes of women with 
AMI. The study of Champney et al. (2007) demonstrated that the overall 
stronger effect of DM among women was more pronounced in the 1990s than in 
more recent years. Eliasson et al. (2008) observed that the survival rates have 
improved in subjects with DM since the early 1980s, more so in women than in 
men, thereby decreasing the gap to non-diabetic women. These findings could 
be associated to the developments in the management strategies of high risk 
AMI patients undergoing PCI.  
The analysis of Kornowski et al. (2012) indicated a profound prognostic 
advantage for drug eluting stents versus bare metal stents among both sexes, 
though women appeared to derive the greatest benefit. This is a possible 
opportunity to improve the outcomes in female AMI patients with DM. It may 
be hypothized that medications such as antiplatelet agents, anticoagulants, and 
beta-blockers may have different effects in women and men with DM (Szerlip 
et Grines 2009). However, there is currently no clear scientific evidence to 
support this hypothesis. It is essential to include more women in future 
randomized controlled studies and find more potent management strategies 
better suited for women with DM.  
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7. CONCLUSIONS 
1. In Estonia, tertiary and secondary care hospitals underwent considerable 
improvement in AMI management between 2001 and 2007. However, 
changes were more pronounced in the tertiary care setting, especially 
with respect to the use of reperfusion and revascularisation. Low rates of 
reperfusion and transfer to PCI clearly need to be addressed in secondary 
care hospitals.  
The improvement in the management of AMI between 2001 and 2007 
in Estonia did not result in a significant decrease in mortality in tertiary or 
secondary care hospitals. Higher age and higher rate of co-morbidities of 
the patients pose a challenge for AMI management. 
2. There were disparities in the process of care and in in-hospital and 1-year 
mortality between the patients first admitted to tertiary care and 
secondary care hospitals in Estonia in 2007. Patients first admitted to 
secondary care hospitals should undergo more vigorous risk stratification 
with invasive and non-invasive methods and the use of evidence-based 
medicine should be encouraged even if cardiac revascularization is not 
provided.  
3. The risk of fatal and non-fatal outcomes is high among patients who have 
undergone PCI. Those with STEMI have worse long-term outcomes than 
those with NSTEMI. This may be explained by the selection of low risk 
NSTEMI patients to undergo PCI. 
4. Diabetic women with AMI who have undergone PCI represent a high-
risk group warranting special attention in management strategies, espe-
cially during hospitalization. There is a need to improve the expertise to 
detect AMI earlier, to reduce disparities in management, and to find 
targeted PCI strategies with adjunctive antithrombotic regimes in women 
with DM.  
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8. FUTURE RESEARCH 
1. Further studies are needed to assess the changes in the management and 
outcomes of AMI patients in hospitals of diferrent levels of care in 
Estonia. This includes the management and outcomes of AMI according 
to sex, age group, and subtype. 
2. Further studies are needed to assess the non-fatal long-term outcomes of 
AMI patients hospitalized into hospitals of different levels of care. 
3. It remains to be evaluated how different patient subgroups adhere to the 
secondary prevention methods of AMI and how it affects their long-term 
fatal and non-fatal outcomes. 
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SUMMARY IN ESTONIAN 
Äge müokardiinfarkt Eestis:  
muutused kliinilistes tunnustes, ravikäsitluses ja -tulemustes  
 
Südame isheemiatõbi (SIT) on üks sagedaseimaid surmapõhjusi maailmas. 
Kõrge elatustasemega lääneriikides on SIT suremus viimase kümnendi jooksul 
oluliselt langenud, mõnedes riikides isegi kuni poole võrra. SIT suremus on 
langenud ka Eestis, kuid sellele vaatamata oleme Euroopas endiselt edetabeli 
esikolmikus. Eestis tuleb lisaks esile tuua just kõrget suremust alla 65 aastaste 
seas. 
Uuringud näitavad, et SIT suremuse vähenemine on 50% ulatuses seletatav 
muutustega peamistes kardiovaskulaarsetes riskitegurites nagu düslipideemia, 
suitsetamine ja kõrge vererõhk. Lisaks mängib olulist rolli uute tõenduspõhiste 
ravimite kasutamine ja revaskulariseerimismeetodite areng ning üha parem 
kättesaadavus. See on toonud kaasa ka ägedasse müokardiinfarkti (ÄMI) 
haigestumuse ja suremuse vähenemise. On teada, et letaalsus ÄMI tõttu esimese 
kuu jooksul võib olla kuni 50% ning ligi pooled surmadest leiavad aset esimese 
paari tunni jooksul alates ataki algusest. Siiski saab patsientide prognoosi 
oluliselt parandada kaasaegsete ravivõtete viivitamatul rakendamisel.  
Sarnaselt teiste Ida-Euroopa riikidega on Eesti meditsiinisüsteemis toimunud 
olulised muutused. Viimase kümnendi jooksul on tehtud suuri jõupingutusi 
ÄMI ravikäsitluse parandamiseks ja ühtlustamiseks. 2001. a. hospitaliseeritud 
ÄMI haigete kohordi põhjal tehtud uuring näitas, et teise ja kolmanda etapi 
haiglates erineb ravikäsitlus olulisel määral. Selgus, et ÄMI patsiente suuna-
takse koronarograafiale harva ja ka perkutaanset koronaarinterventsiooni (PKI) 
rakendatakse vähe – nt ainult neljandikul kolmanda etapi haigla ÄMI patsien-
tidest teostati PKI. Seetõttu on Eestis viimastel aastatel lisaks tõenduspõhiste 
raviskeemide rutiinse kasutamise vajalikkuse rõhutamisele olnud üheks prio-
riteediks suurendada invasiivse reperfusioonravi (PKI) kättesaadavust. Täna on 
tehnilistele nõuetele vastavad ööpäevaringse erakorralise PKI võimalused taga-
tud ainult kolmanda etapi haiglates, tööpäevadel aga plaanilisteks protseduuri-
deks ka juba mitmetes teise etapi haiglates. Arvestades viimasel kümnendil 
tehtud jõupingutusi ÄMI ravikorralduse muutusteks, on oluline hinnata selle 
rakendumist reaalses igapäevases kliinilises praktikas haiglatüübiti ja dünaa-
mikas. Lisaks on tähtis hinnata tervishoiukorralduse muutuste mõju ravitule-
mustele. Varasemalt on Eestis piiratud ligipääsu isikustatud andmetele, mistõttu 
pole olnud võimalik analüüsida erinevate tegurite mõju ÄMI patsientide ravi-
käsitluse hilistulemustele. Vastavad teadmised on aga üliolulised, kui eesmär-
giks on pakkuda võrdset tervishoiuteenuse kvaliteeti kogu Eestis.  
Tänapäeval rõhutatakse järjest enam suurt vajadust kasutada uuringutes 
registriandmeid, mis pärinevad reaalsest kliinilisest igapäevaelust. Ühest küljest 
baseerume küll palju tõenduspõhise meditsiini kontseptsioonile, kuid tuleb 
arvestada, et see põhineb eelkõige randomiseeritud kontrollitud uuringutel, 
kuhu reeglina kaasatakse nooremad, vähemate kaasuvate haigustega, sageda-
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mini meessoost patsiendid. Teisalt, kliinilises igapäevaelus on probleemiks just 
eakate ja naissoost patsientide osakaalu suurenemine, samuti kaasuvate kroo-
niliste haiguste, nagu diabeet, üha suurem esinemissagedus. Näiteks varase-
mates uuringutes on viiteid, et naistel võib diabeet olla seotud kõrgema kardio-
vaskulaarse riskiga kui meestel. Samas, uuringuid diabeetikute soospetsiifiliste 
ravikäsitluse tulemuste kohta peale ÄMI on siiski vähe ning nende tulemused 
on vastukäivad. Need on sageli läbi viidud patsiendikohortidel, kus ainult 
väikesel osal patsientidest on tehtud PKI, mis võib omakorda olla aluseks 
erinevustele ravitulemustes ja olla raskesti interpreteeritavad tänast üha 
invasiivsemat ravikäsitlust arvestades.  
Uurimuse eesmärgid 
1. Hinnata muutusi teise ja kolmanda etapi haiglatesse hospitaliseeritud ÄMI 
patsientide ravikäsitluses ning 30-päeva ja 3-aasta suremuses Eestis aastatel 
2001 vs 2007.  
2. Võrrelda ravikäsitlust, haiglasiseseid ravitulemusi ja 1-aasta suremust teise 
ja kolmanda etapi haiglatesse esmashospitaliseeritud ÄMI patsientide seas 
Eestis 2007. aastal.  
3. Võrrelda STEMI ja NSTEMI patsientide ravi hilistulemusi peale PKI-d, 
seejuures hinnata lisaks suremusele ka korduva mittefataalse ÄMI esinemist 
ja korduva revaskulariseerimise teostamist. 
4. Hinnata ÄMI patsientide soospetsiifilisi ravitulemusi diabeetikutel ja mitte-
diabeetikutel, seejuures hinnates lisaks suremusele ka korduva mittefataalse 
ÄMI esinemist ja korduva revaskulariseerimise teostamist. 
Patsiendid ja metoodika 
Publikatsioonide I ja II andmed pärinesid läbilõikeuuringutest, kus analüüsiti 
2001. ja 2007. aastal Eesti haiglatesse hospitaliseeritud ÄMI haigete ravikäsit-
lust (põhidiagnoosi kood I21–I22 rahvusvahelise haiguste ja nendega seotud 
terviseprobleemide statistilise klassifikatsiooni 10. versiooni (RHK-10) järgi). 
Juhuvalimisse (28% aastate ravijuhtudest) sattunud haigusjuhtude loetelu saadi 
Haigekassa andmebaasist. Uuringu eksperdid analüüsisid haigusjuhtusid 
standardiseeritud uuringuvormi alusel, mis sisaldas andmeid patsientide demo-
graafiliste andmete, kliiniliste tunnuste ning haiglasisese ravikäsitluse ja -tule-
muste kohta. Surma fakti ja kuupäeva andmed haiglajärgselt saadi rahvastiku-
registrist. 
Publikatsioonides III ja IV kajastatud uuringud põhinesid Müokardiin-
farktiregistri (MIR) ning Haigekassa ja rahvastikuregistri andmebaaside 
linkimisel saadud andmetel. MIR on alates 01. jaanuarist 2012 riiklik register, 
millesse kogutakse jooksvalt andmeid hospitaliseeritud ÄMI patsientide kohta 
(RHK-10 koodid I21–I22). MIRi andmekoosseis on kooskõlas projektiga 
„Cardiology Audit and Registration Data Standards in Europe“, mille eesmärk 
on ühtlustada Euroopas ägedate koronaarsündroomide registrite ja auditite 
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raames kogutavate andmete koosseis ning definitsioonid. Analüüsitava lõpp-
valimi moodustasid Tartu Ülikooli Kliinikumi kõik ÄMI patsiendid, kes olid 
hospitaliseeritud ajaperioodil 2006–2009 ning kellel oli tehtud PKI. Patsientide 
isikuandmed ja andmed kliiniliste tunnuste (sh ÄMI alatüüp ja diabeedi 
olemasolu) ning haiglasisese ravikäsitluse ja -tulemuste kohta pärinesid MIRist; 
surma fakti ja kuupäeva andmed haiglajärgselt pärinesid rahvastikuregistrist; 
andmed korduva ÄMI esinemise ning korduvate revaskulariseerimiste teosta-
mise ja meetodi kohta pärinesid Haigekassa andmebaasist. 
Andmete statistiliselt töötlusel kasutati andmetöötlusprogrammi Stata 
(versioon 11) ja R (versioon 2.10.1). 
Uurimuse peamised tulemused ja järeldused 
1. Aastatel 2001 vs 2007 paranes ÄMI patsientide ravikäsitlus nii teise kui 
kolmanda etapi haiglates. Siiski olid soodsad muutused rohkem väljendunud 
kolmanda etapi haiglates, eriti reperfusioonravi ja revaskulariseerimise kasu-
tamise osas. Teise etapi haiglates tuleb rohkem tähelepanu pöörata reper-
fusioonravi rakendamisele ja haigete õigeaegsele suunamisele koronaro-
graafiale.   
Ravikäsitluse paranemine Eestis aastatel 2001 vs 2007 ei toonud kaasa 
suremuse vähenemist haiglates. Patsientide kõrgem iga ja suurenev kardio-
vaskulaarne risk on väljakutseks ÄMI ravikäsitluse edasisel parandamisel.  
2. 2007. aastal esines oluline erinevus teise ja kolmanda etapi haiglatesse 
esmashospitaliseeritud ÄMI patsientide ravikäsitluses ning haiglasiseses- ja 
hilissuremuses. Esmalt teise etapi haiglatesse hospitaliseeritud patsientidel 
tuleks pöörata suuremat rõhku õigeaegsele riski hindamisele mitte-inva-
siivsete ja invasiivsete meetoditega ning julgustada ravijuhistes soovitatud 
ravimite kasutamist, isegi siis kui haiget invasiivsele ravikäsitlusele ei 
suunata. 
3. Peale PKI-d on ÄMI patsientide prognoos tõsine nii fataalsete kui ka mitte-
fataalsete kardiovaskulaarsete tulemusnäitajate esinemise osas. Võrreldes 
NSTEMI patsientidega on STEMI patsientide ravi hilistulemused oluliselt 
halvemad. Erinevused võivad olla tingitud asjaolust, et PKI-le suunatud 
NSTEMI patsientidel on väiksem kardiovaskulaarne risk kui keskmisel 
NSTEMI patsiendil üldiselt.  
4. Koronaarinterventsiooniga ravitud haigetest on just naissoost ÄMI ja dia-
beediga patsiendid kõrgema riskiga grupp, kelle puhul peab pöörama erilist 
tähelepanu kasutatavatele ravistrateegiatele, iseäranis haiglaperioodil. Selle 
kõrge riskiga grupi puhul on oluline parandada oskusi ÄMI varasemaks 
diagnoosimiseks, järgida hoolikamalt ravijuhiste soovitusi ning leida 
suunitletud PKI strateegiaid, mille toeks on soodsa ohutusprofiiliga tõhus 
antitrombootiline raviskeem.  
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